NIH PAR · NCI · R01
PAR-25-243: Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
This Notice of Funding Opportunity (NOFO) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This NOFO is also designed to aid and facilitate the growth of a nationwide…
- NOFO number
- PAR-25-243
- Type
- PAR
- Activity code
- R01
- Primary institute
- NCI · National Cancer Institute
- Clinical trials
- Not Allowed
- Posted
- Nov 18, 2024
- Opens
- Jan 5, 2025
- Expires
- Jan 8, 2028
PAR-25-243 due dates
3 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 05, 2025 | March 05, 2025 * | Not Applicable | July 2025 | October 2025 | December 2025 |
| June 05, 2025 | July 05, 2025 * | Not Applicable | November 2025 | January 2026 | April 2026 |
| October 05, 2025 | November 05, 2025 * | Not Applicable | March 2026 | May 2026 | July 2026 |
| February 05, 2026 | March 05, 2026 * | Not Applicable | July 2026 | October 2026 | December 2026 |
| June 05, 2026 | July 05, 2026 * | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 05, 2026 | November 05, 2026 * | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 05, 2027 | March 05, 2027 * | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 05, 2027 | July 05, 2027 * | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 05, 2027 | November 05, 2027 * | Not Applicable | March 2028 | May 2028 | July 2028 |
Projects funded under PAR-25-243
NIH RePORTER lists 10 projects funded under PAR-25-243 in FY2022–FY2026, with $6.4M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
10
Distinct projects, FY2022–FY2026
New awards
9
Type 1 (new project) award records
NIH funding
$6.4M
Award dollars under PAR-25-243, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 10 | 9 | $6.4M |
Institutions with the most funding
- Beckman Research Institute/City of Hope$738K · 1 project
- Children's Hosp of Philadelphia$736K · 1 project
- Sloan-Kettering Inst Can Research$691K · 1 project
- University of Pittsburgh at Pittsburgh$674K · 1 project
- Johns Hopkins University$658K · 1 project
- Univ of North Carolina Chapel Hill$639K · 1 project
- Comprehensive Cancer Center/ Univ/Pr$591K · 1 project
- University of Michigan at Ann Arbor$558K · 1 project
Most recent new awards
- Immune Dysfunction, Social Determinants of Health, and Ovarian Cancer Outcome Differences (opens NIH RePORTER)
University of Pittsburgh at Pittsburgh · 1R01CA302879-01A1 · NCI · Notice Sep 17, 2026
$674KR01
- The impact of genetic ancestry on Notch1 activation and signaling in T-ALL (opens NIH RePORTER)
Children's Hosp of Philadelphia · 1R01CA315128-01 · NCI · Notice Sep 14, 2026
$736KR01
- Investigating the Molecular Effects of Social Deprivation on Neuroblastoma Tumorigenesis and Progression (opens NIH RePORTER)
University of Michigan at Ann Arbor · 1R01CA299014-01A1 · NCI · Notice Sep 10, 2026
$558KR01
- Elucidating gut microbiota-driven Tuft-2 cell expansion as a risk factor for neoplastic adenoma development in early-onset CRC among black US residents (opens NIH RePORTER)
Cleveland Clinic Lerner Com-Cwru · 1R37CA315065-01 · NCI · Notice Sep 2, 2026
$544KR37
- Dissecting the Role of Inherited Non-Coding Variants in the Enhancer Architecture of Breast Cancer (opens NIH RePORTER)
Comprehensive Cancer Center/ Univ/Pr · 1R01CA316861-01 · NCI · Notice Aug 27, 2026
$591KR01
- Identification of Biological Mechanisms and Risk Factors Contributing to Progression of DCIS to Invasive Breast cancer among AANHPI Populations. (opens NIH RePORTER)
University of Hawaii at Manoa · 1R01CA301785-01A1 · NCI · Notice Aug 13, 2026
$556KR01
What its predecessor PAR-24-277 funded
PAR-25-243 reissues PAR-24-277. Its funding history is the best guide to who wins under this program: 2 projects and $2.4M in FY2022–FY2026.
Projects funded
2
Distinct projects, FY2022–FY2026
New awards
2
Type 1 (new project) award records
NIH funding
$2.4M
Award dollars under PAR-24-277, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 2 | 2 | $1.2M |
| FY2026 | 2 | 0 | $1.2M |
Institutions with the most funding
- Northwestern University$1.4M · 1 project
- Case Western Reserve University$1.0M · 1 project
Most recent new awards
- The role of adverse social-biological interactions in acute myeloid leukemia disparities (opens NIH RePORTER)
Northwestern University · 1R01CA295626-01A1 · NCI · Notice Aug 28, 2025
$727KR01
- Biological factors driving clinical outcomes in HPV+ oropharyngeal cancer (opens NIH RePORTER)
Case Western Reserve University · 1R37CA302718-01 · NCI · Notice Aug 22, 2025
$511KR37
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-243. Contact the program officer at the institute that fits your research before applying.
- NCI · National Cancer Institute
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Award terms
- Application types allowed
- NewRenewalResubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are not limited but need to reflect the actual needs of the proposed project.
- Project period
- The maximum project period is 5 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-24-277.
- Companion NOFOs: PAR-25-244.
Other open NOFOs for R01
- PAR-25-336Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)NCI · next due Nov 16, 2026
- PAR-27-072Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-25-337Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-25-338Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
- PA-25-172Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)NCI · next due Feb 5, 2027
- PAR-24-311Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)NCI · next due Feb 5, 2027
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.